Head and neck cancer committee

International Journal of Radiation Oncology Biology Physics

Volumn 51, Issue 3, 2001, Pages 39-43

  Ang, Kian ^a   Weber, Randal ^a   Vokes, Everett ^b   Trotti, Andy ^c   Chapman, Donald ^d   Cooper, Jay ^e   Forastiere, Arlene ^b   Fu, Karen K ^f   Hammond, Elizabeth ^d   Khuri, Fadlo ^g   Leveque, Francis G ^h   Leupold, Nancy ⁱ   Eisbruch, Avraham ^j   Mack, Curtis ^k   Mukherji, Suresh ^l   Pajak, Thomas F ^m   Ridge, John A ^a  

^a Surgical Oncology Committee   (United States)

^b Medical Oncology Committee   (United States)

^c Quality of Life Committee   (United States)

^d Translational Research Program Committee   (United States)

^e Executive Committee   (United States)

^f Past Committee   (United States)

^g Chemoprevention Committee   (United States)

^h Cancer Prevention and Control Program   (United States)

ⁱ Patient Advocacy Committee   (United States)

^j Image Guided Radiotherapy Committee   (United States)

^k Cancer Prevention and Control Committee   (United States)

^l American College of Radiology Imaging Network   (United States)

^m Statistician   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL; FORECASTING; HEAD AND NECK TUMOR; HUMAN; METHODOLOGY; MULTIMODALITY CANCER THERAPY; ONCOLOGY; ORGANIZATION AND MANAGEMENT; PROFESSIONAL STANDARD; SECOND CANCER; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CHEMOPROPHYLAXIS; DRUG EFFICACY; HEAD AND NECK CARCINOMA; HYPOSALIVATION; LARYNX CARCINOMA; MUCOSA INFLAMMATION; ORGAN PRESERVATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; SQUAMOUS CELL CARCINOMA;

CLINICAL TRIALS; COMBINED MODALITY THERAPY; FORECASTING; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASMS, SECOND PRIMARY; PROFESSIONAL STAFF COMMITTEES; RADIATION ONCOLOGY; RESEARCH DESIGN;

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOOXYGENASE 2; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; HYDROXYUREA; MISOPROSTOL; PACLITAXEL; PILOCARPINE; TUMOR MARKER;

EID: 0034778077     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)01778-3     Document Type: Article

References (22)

1. Second malignancies in patients who have head and neck cancer: Incidence, effect on survival and implications based on the RTOG experience
2. Precisely defining high-risk operable head and neck tumors based on RTOG 85-03 and 88-24: Targets for postoperative radiochemotherapy?
3. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinomas: A secondary analysis of RTOG 85-27
4. Cancer Statistics, 2000
5. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003
6. Altered fractionation in head and neck cancer
7. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: Final analysis of a randomized trial of the EORTC cooperative group of radiotherapy
8. Conventional radiotherapy as the primary treatment of squamous cell carcinoma (SCC) of the head and neck: A randomized multicenter study of 5 versus 6 fractions per week- Preliminary report from DAHANCA 6 and 7 trial
9. Importance of overall time factor in postoperative radiotherapy
10. A randomized trial of accelerated versus conventional radiotherapy in head and neck cancer
11. Randomized clinical trial of accelerated 7 days per week fractionation in radiotherapy for head and neck cancer: Preliminary report on treatment toxicity
12. Accelerated fractionation (AF) compared to conventional fractionation (CF) improved head, and neck cancers: Results of the EROTC 22851 randomized trial
13. A randomized multicentre trial of CHART versus conventional radiotherapy in head and neck cancer
14. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer
15. Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial
16. A phase III comparison of standard radiation therapy (RT) versus RT plus concurrent cisplatin (DDP) versus split-course RT plus concurrent DDP and 5-fluorouracil (5FU) in patients with unresectable squamous cell head and neck cancer (SCHNC): An intergroup study
17. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study
18. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma
19. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer
20. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: A meta-analysis of prospective and randomized trials
21. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer
22. Molecular markers as prognostic factors for local recurrence and radioresistance in head and neck squamous cell carcinoma